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Abstract
It is conventional strategy to treat highly malignant brain tumors initially with cytoreductive surgery
followed by adjuvant radio- and chemotherapy. However, in spite of all such efforts, the patients'
prognosis remains dismal since residual glioma cells continue to infiltrate adjacent parenchyma and
the tumors almost always recur. On the basis of a simple biomechanical conjecture that we have
introduced previously, we argue here that by affecting the 'volume-pressure' relationship and
minimizing surface tension of the remaining tumor cells, gross total resection may have an inductive
effect on the invasiveness of the tumor cells left behind. Potential implications for treatment
strategies are discussed.
Background
Malignant brain tumors such as gliomas expand through
proliferation and invasion within the confines of the bony
skull, hence in a mechanically constraint area. That is, the
brain tissue's mechanical 'reserve' rooms, i.e. the intersti-
tial space, the cerebrospinal fluid filled ventricles and the
vascular system can only temporarily compensate,
through fluid shifts, any sudden or even gradual increase
in intracranial pressure (ICP) as it relates to e.g. an intrac-
erebral hemorrhage or a tumor. Once the point of decom-
pensation is reached (Figure 1) any even miniscule
increase in volume will trigger a massive, life-threatening
increase in ICP [1] that generally leads to surgical inter-
vention in an attempt to resect some of this pressure-rais-
ing volume.
Standard treatment for highly aggressive gliomas (ana-
plastic astrocytomas and glioblastomas (GBM)) has there-
fore changed little over the years and still consists of gross
surgical resection followed by adjuvant radiotherapy and
chemotherapy (e.g., [2]). The problem is that the already
spatially disseminated tumor cannot be visualized at the
single cell level with current clinical imaging modalities,
let alone be removed completely. Hence, after a period of
temporary betterment, the tumor almost always returns,
primarily locally, i.e., at the surgical edge, in conjunction
with widespread tissue invasion that at some point pro-
hibits further cytoreductive therapy. Therefore, regardless
of any treatment, the grim outcome overall did not change
in decades with most GBM patients succumbing to the
disease within 1–2 years after diagnosis (e.g., [3]). New
approaches are therefore desperately needed and, as
always, the development of innovative strategies starts
with a better understanding of the current limitations.
Here, we discuss, from a pure theoretical and simple
mechanistic perspective, if the first line approach of surgi-
cal debulking has any impact on the characteristic inva-
sive behaviour of these cancer systems post-extirpation of
the tumor core.
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Hypothesis
Presentation
In vitro, invasive gliomas display finger-like invasive pat-
terns in three-dimensional extracellular matrix environ-
ments [4], not unlike the chain-like migration seen from
gliomas in vivo by following axonal fiber tracts and blood
vessels [5,6]. Such 'fingering' morphology is common in
other physical contexts as well: for instance, (i) when a
'crack' occurs in a solid specimen experiencing a point-like
internal breakage or, with a growing inclusion inside [7],
(ii) when a drop of liquid is injected in a more viscous
environment ('Hele-Shaw' effect), or (iii) when a liquid
drop impacts on a solid surface, causing the formation of
a fluid 'crown' ('Rayleigh' or 'Yarin-Weiss' capillary insta-
bility [8]). Detailed investigations of these models predict
the number N  of fingers which are expected to form
depending on the characteristics of the media. Notably,
under some very general assumptions, the number of
parameters to be accounted for predicting N is very low,
and can be reduced to the radius R of the 'drop' or of the
inclusion, the external pressure P which acts on it and
finally, the surface tension σ.
As previously proposed in [9], based on Eq. (1), a dimen-
sionless Invasion Parameter, IP, can be defined assuming
that invasion occurs (IP > 1) when N ≥ 1.
IP = PR/σ (2)
Here,  P  stands for the confining mechanical pressure
exerted by the microenvironment on the tumor, R for the
radius of the tumor, and σ for the tension at the tumor
surface. According to Eq. (2), invasive cell behaviour is to
be expected in all but for the case of IP < 1 (which implies
large tumor surface tension, small confining pressure and/
or small tumor radius values).
In the case of malignant gliomas, surgical debulking is
geared to reduce the tumor burden, hence R  should
decrease, which in turn would diminish the product PR
and result in an overall IP decline, if σ would to remain
constant. To be more specific, according to Schettini and
Walsh [10] the reduction of an intracranial balloon vol-
ume from 6 ml to 0.5 ml (i.e., of a factor of 12) would pro-
duce a reduction of the product PR, being P  the
intracranial pressure measured in the ipsilateral ventricle
of a factor ranging from 24 to 8.8 mmHg, i.e., roughly of
an order of magnitude. Such measurements, however, are
performed 'acutely', i.e., before compensatory mecha-
nisms, due to both the nonlinear viscoelastic behaviour of
the brain and circulatory autoregulation, are elicited.
Therefore, on a closer look, there are a few important cave-
ats:
• First, this 'volume-pressure' relationship or elastance
(and its inverse quantity, compliance) found for the
inflated epidural balloon in experimental settings should,
in reality, only hold for benign tumors that grow strictly
compressive and non-infiltrative in nature such as most
meningiomas [11]. In fact, Hase et al. [1] already com-
pared the ICP dynamics post-surgery for such meningi-
omas versus astrocytomas. The authors reported a higher
elastance for meningiomas (comparable to the solid line
in Figure 1), as compared to a lower elastance for malig-
nant astrocytomas (suggested as dotted line; see also Table
3 in [1]). That is, in astrocytomas, the same increase in
volume leads to a lesser increase in ICP. We argue that the
distinct infiltrative nature of these malignant tumors is
responsible for causing such 'favourable' mechanical con-
ditions for the neoplasm. (Gliomas for instance release
the neutotoxicity-inducing excitatory amino acid gluta-
mate [12] and produce matrix degrading enzymes or met-
alloproteinases [13] which together can impact and
disrupt surrounding tissue architecture, as seen on diffu-
sion tensor NMR [14,15]. None of the complicated bio-
chemical processes driving tumor progression is explicitly
included in our hypothesis here; rather, we focus on some
simple biomechanical aspects involved). Further, this
may delay the onset of purely pressure-related symptoms
which in turn can help explain the surprisingly large sizes
of some of these malignant tumors at the time of diagno-
sis. Conversely, surgically reducing tumor volume will
also lead to a relatively smaller rate of reduction in P.
Returning then to Eq. (2), post-surgical intervention, the
N
PR
≈
σ
(1)
Intracranial pressure-volume curve Figure 1
Intracranial pressure-volume curve. In the case of 
lower elastance (dotted line), the same increase in volume 
leads to a lower intracranial pressure increase than in the 
case of higher elastance (solid line) (from Hase et al. [1], with 
permission).Annals of Surgical Innovation and Research 2008, 2:1 http://www.asir-journal.com/content/2/1/1
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PR product may remain elevated and any sub-total resec-
tion (with a sizeable portion of R remaining) will only
add to this tendency.
• Secondly, by definition, gross total resection will aim to
remove the (on conventional imaging, now generally
nuclear magnetic resonance, or NMR, imaging) visible
surface of the tumor. The Laplace law should hold for the
resulting spherical shell and thus, σ should, if anything,
become very small postoperatively which in turn would
yield an excessive increase in IP for the remaining, already
disseminated cancer cells that remain below the current
imaging resolution. It is noteworthy in that context that
dexamethasone, a glucocorticosteroid often used peri-
operatively with the idea of treating tumoral edema for-
mation, has been shown to also increase the surface ten-
sion of the malignant astrocytoma cell lines U-87MG, U-
118MG and LN-229 [16]. One could therefore argue that
this effect may be one reason why peri-operative steroid
therapy is effective to some degree.
• And finally, adding the experimentally proven notion
that more invasive cells move faster on stiffer substrates
[17-19] to the aforementioned lower elastance of astrocy-
tomas post-extirpation also makes for an invasiveness-
promoting microenvironment for the remaining tumor
cell formations.
Implications
In Guiot et al. [9] we had deduced from Eq. (2) that
increasing σ (e.g., through stable E-cadherin transfection
as described already for prostate cancer cells in [20]), as
well as reducing P and R are the rather obvious, distinct
therapeutic goals. While this remains correct, what
deserves a more careful evaluation is their relationship par-
ticularly within the anatomic confines of a host organ
such as the brain. Surgical impact, while reducing R, tem-
porarily relieving P and thus at least subjectively improv-
ing the patient's symptoms can, for the reasons stated
above, potentially have detrimental inductive effects on
tumor invasion for the cells left behind, which are gener-
ally believed to significantly contribute to recurrence and
treatment failure (e.g., [21]). One could therefore argue,
that surgery fails to prevent if not even facilitates the tran-
sition of the tumor from a rather volumetric growth proc-
ess to a more diffusely expanding system, where
infiltrating glioma cells can switch to a proliferative phe-
notype and vice versa [22]; since such single cell dynamics
remain hidden largely below the current NMR imaging
threshold, this spatio-temporally propagating system now
provides the clinician with lesser if any macroscopic tar-
gets to go after, up until a sizeable tumor recurs. However,
suggesting not to operate would be irresponsible since the
severity of clinical symptoms all too often mandates rapid
surgical ICP relief and, not surprisingly, numerous studies
have shown that gross total resection improves the
patient's disease-free interval (e.g., [23]). That is, aside
from obtaining tissue for a histo-pathological confirma-
tion of tumor grade, the main biomechanical goal of any
surgical intervention is to approximate the flat part of Fig-
ure 1. Our conjecture only cautions about the standard
approach's potential side effects on the invasive cells left
behind and, in doing so, (1) confirms the indication for
pharmaceutical peri-operative ICP reduction, and (2)
reemphasizes the desperate need for effective anti-inva-
sive targeting modalities that are administered in conjunc-
tion with surgery (and conventional adjuvant regimen).
(Surgery of solid malignant tumors usually attempts to
excise larger margins in healthy tissue which, however, is
a limited option in the brain where any even minimal tis-
sue damage can add to the functional deficit already
caused by the tumor).
The former (1) refers also to avoiding an effective increase
in P, known as an 'ICP rebound phenomenon' that can
occur e.g. when the osmotic diuretic agent Mannitol
(administered to treat elevated ICP) extravasates into the
tissue which in turn can cause a reverse osmotic shift and
thus a detrimental raise in ICP [24]. Given that glucocor-
ticoids are still the treatment of choice, one would hope
for a renaissance of the pharmaceutical field that is geared
towards intracranial pressure reduction. The latter (2)
supports for instance further development of the recently
introduced anti-angiogenesis compounds. They are
designed to impact the nutrient supply system (by target-
ing integrin receptors [25] or related growth factors such
as VEGF [26]), thus supposedly help manage the PR
dynamics of any residual or recurrent tumor; in doing so,
they should also impact structural dissemination routes
for invasive glioma cells which are known to move along
the perivascular space amongst others [27]. Interestingly,
the perivascular space seems to be also a permissive loca-
tion of cancer stem cells [28] that have been implicated in
the development of treatment resistance [29]. Taken
together, while recent results raise some caution [30], so
far anti-angiogenetic drugs remain a promising strategy as
we have argued already in [31] on the basis of organ spe-
cific albeit limited carrying capacity.
In summary, following a primarily biomechanical conjec-
ture, the impact caused by undoubtedly necessary surgical
intervention may have unintended, inductive effects on
invasiveness of the glioma cells left behind. This empha-
sizes the need for pharmaceutical peri-operative ICP
reduction, and supports innovative strategies geared
directly towards targeting disseminated cells.
Competing interests
The author(s) declare that they have no competing inter-
ests.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Annals of Surgical Innovation and Research 2008, 2:1 http://www.asir-journal.com/content/2/1/1
Page 4 of 4
(page number not for citation purposes)
Authors' contributions
TSD developed the hypothesis and drafted the manu-
script, with CG being responsible for the mathematical
description. Both authors read and approved the final
manuscript.
Acknowledgements
This work has been supported in part by NIH grants CA 085139 and CA 
113004 and by the Harvard-MIT (HST) Athinoula A. Martinos Center for 
Biomedical Imaging and the Department of Radiology at Massachusetts 
General Hospital. We thank Dr. Roger Haertl (Department of Neurosur-
gery, New York Hospital & Cornell University) for critical review of the 
manuscript.
References
1. Hase U, Reulen HJ, Schuber R, Schuerman K: The course of intrac-
ranial pressure and volume-pressure relationships following
extirpation of meningiomas and astrocytomas.  Acta Neurochir
1978, 44(3–4):161-171.
2. Norden AD, Wen PY: Glioma therapy in adults.  Neurologist 2006,
12(6):279-292.
3. Ohgaki H, Kleihues P: Genetic pathways to primary and sec-
ondary glioblastoma.  Am J Pathol 2007, 170(5):1445-1453.
4. Deisboeck TS, Berens ME, Kansal AR, Torquato S, Stemmer-Rach-
amimov AO, Chiocca EA: Pattern of self-organization in
tumour systems: complex growth dynamics in a novel brain
tumour spheroid model.  Cell Prolif 2001, 34(2):115-134.
5. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P:
Transplanted glioma cells migrate and proliferate on host
brain vasculature: a dynamic analysis.  Glia 2006,
53(8):799-808.
6. Friedl P, Wolf K: Tumour-cell invasion and migration: diversity
and escape mechanisms.  Nat Rev Cancer 2003, 3(5):362-374.
7. Guiot C, Pugno N, Delsanto PP: Elastomechanic model of tumor
invasion.  Appl Phys Lett 2006, 89:233901-233903.
8. Yarin AL: Drop impact dynamics: splashing, spreading, reced-
ing, bouncing.  Ann Rev Fluid Mech 2006, 38:159-192.
9. Guiot CG, Delsanto PP, Deisboeck TS: Morphological instability
and cancer invasion: a 'splashing water drop' analogy.  Theor
Biol Med Model 2007, 4:4.
10. Schettini A, Walsh EK: Brain tissue elastic behavior and exper-
imental brain compression.  Am J Physiol 1988,
255(5Pt2):R799-805.
11. Whittle IR, Smith C, Navoo P, Collie D: Meningiomas.  Lancet 2004,
363(9420):1535-1543.
12. Takano T, Lin JH-C, Arcuino G, Gao Q, Yang J, Nedergaard M:
Glutamate release promotes growth of malignant gliomas.
Nat Med 2001, 7(9):1010-1015.
13. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J: Matrix
metalloproteinases and tissue inhibitors of metalloprotein-
ases in human gliomas.  J Neurosurg 1995, 83(2):298-307.
14. Price SJ, Burnet NG, Donovan T, Green HAL, Pena A, Antoun NM,
Pickard JD, Carpenter TA, Gillard JH: Diffusion tensor imaging of
brain tumours at 3T: a potential tool for assessing white
matter tract invasion?  Clin Radiol 2003, 58(6):455-462.
15. Talos I-F, Zou KH, Kikinis R, Jolesz FA: Volumetric assessment of
tumor infiltration of adjacent white matter based on ana-
tomic MRI and diffusion tensor tractography.  Acad Radiol 2007,
14(4):431-436.
16. Winters BS, Shepard SR, Foty RA: Biophysical measurements of
brain tumor cohesion.  Int J Cancer 2005, 114(3):371-379.
17. Georges PC, Janmey PA: Cell type-specific response to growth
on soft materials.  J Appl Physiol 2005, 98(4):1547-1553.
18. Kaufman LJ, Brangwynne CP, Kasza KE, Filippidi E, Gordon VD, Deis-
boeck TS, Weitz DA: Glioma expansion in collagen I matrices:
analyzing collagen concentration-dependent growth and
motility patterns.  Biophysical J 2005, 89(1):635-650.
19. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A,
Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer
DA, Weaver VM: Tensional homeostasis and the malignant
phenotype.  Cancer Cell 2005, 8(3):241-254.
20. Luo J, Lubaroff DM, Hendrix MJC: Suppression of prostate can-
cer invasive potential and matrix metalloproteinase activity
by E-cadherin transfection.  Cancer Res 1999, 59(15):3552-3665.
21. Giese A, Bjerkvig R, Berens ME, Westphal M: Cost of migration:
invasion of malignant gliomas and implications for treat-
ment.  J Clin Oncol 2003, 21(8):1624-1636.
22. Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME:
Dichotomy of astrocytoma migration and proliferation.  Int J
Cancer 1996, 67(2):275-282.
23. Mineo JF, Bordron A, Baroncini M, Ramirez C, Maurage CA, Blond S,
Dam-Hieu P: Prognosis factors of survival time in patients with
glioblastoma multiforme: a multivariate analysis of 340
patients.  Acta Neurochir 2007, 149(3):245-253.
24. Palma L, Bruni G, Fiaschi AI, Mariotti A: Passage of mannitol into
the brain around gliomas: a potential cause of rebound phe-
nomenon.  A study on 21 patients.   J Neurosurg Sci 2006,
50(3):63-66.
25. Narbors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher
JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD,
Grossman SA: Phase I and correlative biology study of cilen-
gitide in patients with recurrent malignant glioma.  J Clin Oncol
2007, 25(13):1651-1657.
26. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS: Anticancer
therapies combining antiangiogenic and tumor cell cytotoxic
effects reduce the tumor stem-like cell fraction in glioma
xenograft tumors.  Cancer Res 2007, 67(8):3560-3564.
27. Guillamo JS, Lisovoski F, Christov C, Le Guerinel C, Defer GL,
Peschanski M, Lefrancois T: Migration pathways of human gliob-
lastoma cells xenografted into the immunosuppressed rat
brain.  J Neurooncol 2001, 52(3):205-215.
28. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B,
Oh EY, Gaber MW, Finkelstein D, Allen M, Frank A, Bayazitov IT,
Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ: A perivascular
niche for brain tumor stem cells.  Cancer Cell 2007, 11(1):69-82.
29. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst
MW, Bigner DD, Rich JN: Glioma stem cells promote radiore-
sistance by preferential activation of the DNA damage
response.  Nature 2006, 444(7120):756-760.
30. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL,
Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY: Bev-
acizumab for recurrent malignant gliomas: efficacy, toxicity
and patterns of recurrence.  Neurology 2008, 70(10):779-787.
31. Deisboeck TS, Wang Z: Cancer dissemination: a consequence
of limited carrying capacity?  Med Hypotheses 2007,
69(1):173-177.